Kailer: Looking ahead to 2026, the expected increase in operating revenue is forecasted to be 19%-22%.

On April 3rd, Kai Leiying stated at the performance briefing that the company expects a 19%-22% growth in revenue for the year 2026. In terms of business sectors, the small molecule business is currently in an adjustment phase, with commercial projects showing promising performance and overall stability. Emerging businesses are expected to continue to maintain a high growth trend, while performance in the two large molecule business sectors is expected to be more outstanding.